Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Intern Med ; 2024 Feb 26.
Article in English | MEDLINE | ID: mdl-38403763

ABSTRACT

Atypical hemolytic uremic syndrome (aHUS) is a type of HUS. We herein report a case of aHUS triggered by pancreatitis in a patient with a heterozygous variant of membrane cofactor protein (MCP; P165S), a complement-related gene. Plasma exchange therapy and hemodialysis improved thrombocytopenia and anemia without leading to end-stage kidney disease. This MCP heterozygous variant was insufficient to cause aHUS on its own. Pancreatitis, in addition to a genetic background with a MCP heterozygous variant, led to the manifestation of aHUS. This case supports the "multiple hit theory" that several factors are required for the manifestation of aHUS.

2.
Rinsho Ketsueki ; 63(3): 201-205, 2022.
Article in Japanese | MEDLINE | ID: mdl-35387933

ABSTRACT

The patient is a 34-year-old HIV antibody-negative female with normal immunocompetence. The patient was referred to the hospital of the current study due to diarrhea and abdominal pain, which developed in May 2014. On conducting computed tomography (CT), remarkable wall thickening was noted in the terminal ilium over the ascending colon, suggesting a malignant tumor. However, making a definite diagnosis by lower gastrointestinal endoscopic biopsy and left hemicolectomy was not possible. The dense proliferation of plasma cell-like cells and plasmablasts was noted; CD20, CD19, CD79a, CD3, CD4, and Epstein-Barr virus-encoded miRNAs (EBER) were negative and CD138 was positive on immunostaining. Based on the aforementioned data, the patient was diagnosed with plasmablastic lymphoma (PBL). High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation (PBSCT) was performed in the first remission period after the completion of four cycles of hyper CVAD/MTX-AraC alternating therapy. Remission was confirmed by FDG-PET/CT 3 months after autologous PBSCT. No signs of recurrence have been observed in 6 years after the transplantation. Although no standard treatment for PBL has been established, autologous peripheral blood stem cell transplantation combined with high-dose chemotherapy during the first remission period may be a beneficial treatment option.


Subject(s)
Epstein-Barr Virus Infections , HIV Infections , Peripheral Blood Stem Cell Transplantation , Plasmablastic Lymphoma , Adult , Antineoplastic Combined Chemotherapy Protocols , Female , HIV Infections/complications , Herpesvirus 4, Human , Humans , Plasmablastic Lymphoma/diagnosis , Plasmablastic Lymphoma/therapy , Positron Emission Tomography Computed Tomography , Transplantation, Autologous
3.
Int J Pharm ; 609: 121185, 2021 Nov 20.
Article in English | MEDLINE | ID: mdl-34655708

ABSTRACT

Intravitreal injections of vancomycin (VCM) and ceftazidime (CAZ) are commonly used to treat infectious endophthalmitis. When patient cases require retinal detachment with silicone oil (SO) tamponade, the antibiotic doses are empirically reduced to 25 %. Currently, there is no scientific evidence for these empirical dose reductions. The purpose of the present study is to determine the quantitative impact that SO tamponades have on intraocular VCM pharmacokinetics. Because of high invasiveness of frequent sampling of intraocular VCM concentrations in human, this pharmacokinetic study was performed in cynomolgus monkey's eyes. Population pharmacokinetic modeling and simulation were performed using 75 different intraocular VCM concentrations obtained from 8 male cynomolgus monkeys. A one-compartment model with a first-order diffusion rate was used as a structural pharmacokinetic model. From the covariate analysis, SO tamponade significantly decreased the volume of distribution while pars plana vitrectomy with lensectomy (PPV) significantly increased the clearance and diffusion rate constants. From the Monte Carlo simulation (n = 1,000), the median time above minimum inhibitory concentration (T>MIC, a therapeutic effect index) durations of SO and normal eyes at clinical doses of 1,000 µg were 2.6 and 11.0 days, respectively. Using intravitreal injections of VCM with SO tamponade or PPV may reduce the therapeutic effect.


Subject(s)
Retinal Detachment , Silicone Oils , Animals , Humans , Macaca fascicularis , Male , Retinal Detachment/surgery , Retrospective Studies , Vancomycin , Vitrectomy
4.
Transl Vis Sci Technol ; 10(3): 1, 2021 03 01.
Article in English | MEDLINE | ID: mdl-34003935

ABSTRACT

Purpose: This study evaluated the pharmacokinetics of intravitreal vancomycin and ceftazidime in the aqueous humor of macaque eyes filled with silicone oil in the vitreous cavity. Methods: Intravitreal vancomycin (1 mg/0.1 mL) and ceftazidime (2 mg/0.1 mL) were injected into four normal macaque eyes, four vitrectomized aphakic macaque eyes, and four previously vitrectomized aphakic macaque eyes filled with silicone oil (silicone oil-filled eyes). Aqueous humor samples (0.1 mL) were obtained just before injection and at 2 and 5 hours and 1, 2, 3, 5, 7, and 10 days after injection. In each group, corneal endothelial cell density (ECD) measurements and electroretinogram (ERG) recordings were obtained before injection and after 1 month. Results: The half-lives of vancomycin in the aqueous humor of normal, vitrectomized, and silicone oil-filled eyes were 29.4, 21.1, and 6.8 hours, respectively, and those of ceftazidime were 20.4, 5.2, and 3.1 hours, respectively. The maximum vancomycin aqueous humor concentrations of normal, vitrectomized, and silicone oil-filled eyes were 151.4, 205.6, and 543.5 µg/mL, respectively, and the maximum ceftazidime aqueous humor concentrations are 64.6, 260.0, and 1176.3 µg/mL, respectively. There was no change in ECD, and ERG was not declined after intravitreal injection in all groups. Conclusions: The half-lives of vancomycin and ceftazidime in the aqueous humor were shorter in silicone oil-filled eyes than in normal and vitrectomized eyes. High antibiotic concentrations in silicone oil-filled eyes seemed to be well tolerated. Translational Relevance: This study aids in estimating how often an antibiotic should be intravitreally injected for endophthalmitis of silicone oil-filled eyes.


Subject(s)
Ceftazidime , Silicone Oils , Animals , Macaca , Vancomycin , Vitrectomy/veterinary , Vitreous Body
5.
Rinsho Ketsueki ; 62(12): 1672-1677, 2021.
Article in Japanese | MEDLINE | ID: mdl-35022335

ABSTRACT

An 83-year-old man was diagnosed with hairy cell leukemia (HCL). He was treated with cladribine and achieved partial remission. However, pancytopenia due to HCL bone marrow involvement progressed slowly. Nine years later, he developed rectal cancer. Prior to the surgery, endoscopy-assisted submucosal ink injection was performed to identify the area of lower intestinal lesions. The following day, he developed septic peritonitis with shock status, perhaps due to his neutropenia and ink injection procedures. Surgical resection of the cancer was presumed unfeasible; therefore, radiation was performed. Several months later, bone marrow examination revealed HCL infiltration with reticulin fibrosis. Chemotherapy regimens with purine nucleoside analogs, which are the standard treatments for HCL, might accentuate the progression of his rectal cancer and enhance the development of severe infections. Therefore, interferon (IFN) -α was administered as an alternative therapy. Three months later, pancytopenia resolved, and bone marrow examination revealed a remarkable improvement in HCL infiltration and marrow fibrosis. With IFN-α therapy, the patient successfully underwent surgical resection of the rectal cancer. Using INF-α, a prompt recovery from pancytopenia might be expected even in a patient with advanced HCL, who requires surgical treatment for a concomitant cancer.


Subject(s)
Antineoplastic Agents , Leukemia, Hairy Cell , Rectal Neoplasms , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Bone Marrow , Cladribine/therapeutic use , Humans , Interferon-alpha/therapeutic use , Leukemia, Hairy Cell/complications , Leukemia, Hairy Cell/drug therapy , Male , Rectal Neoplasms/drug therapy , Rectal Neoplasms/surgery
6.
Rinsho Ketsueki ; 61(4): 301-304, 2020.
Article in Japanese | MEDLINE | ID: mdl-32378570

ABSTRACT

A 64-year-old man presented with abnormal imaging results on 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET), showing moderately increased FDG-uptake in the entire bone marrow. Blood tests revealed leukocytosis, thrombocytosis, and increased lactate dehydrogenase levels. Furthermore, the neutrophil alkaline phosphatase score decreased. Bone marrow examination revealed marked hypercellularity of myeloid and megakaryocytic lineages without an excess of blasts. Cytogenetic analysis of the bone marrow demonstrated Philadelphia chromosome, and fluorescence in situ hybridization analysis was positive for BCR-ABL1 fusion genes. Thus, the patient was diagnosed with chronic myeloid leukemia (CML) in the chronic phase and tyrosine kinase inhibitor therapy with 100 mg of dasatinib daily was initiated. Complete cytogenetic response and a major molecular response were achieved at 3 and 12 months post-treatment, respectively. FDG-uptake values of the bone marrow remarkably decreased along with the remission status of the disease. FDG-PET images at pre- and post-treatment of CML are rarely compared, so we report this case as an important reference.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Fluorodeoxyglucose F18 , Fusion Proteins, bcr-abl , Humans , In Situ Hybridization, Fluorescence , Male , Middle Aged , Positron-Emission Tomography , Protein Kinase Inhibitors
7.
Acta Biomater ; 87: 187-196, 2019 03 15.
Article in English | MEDLINE | ID: mdl-30710709

ABSTRACT

The existing first-generation drug-eluting stent (DES) has caused late and very late stent thrombosis related to incomplete stent endothelialization. Hence, biomaterials that possess sufficient anti-thrombogenicity and endothelialization with the controlled drug release system have been highly required. In this work, we have developed a newly designed drug-release platform composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer, a non-thrombogenic polymer, and micropatterned hydrogenated amorphous carbon (a-C:H), a cell-compatible thin film. The platelet adhesion and the endothelial cell adhesion behavior on the micropatterned substrates were investigated in vitro. The results indicated that the micropatterned a-C:H/MPC polymer substrates effectively supported the human umbilical vein endothelial cell (HUVEC) proliferation, while suppressing the platelet adhesion. Interestingly, the HUVEC exhibited different shape and behavior by changing the island size of the micropatterned a-C:H. By introducing both a non-thrombogenic polymer and cell-compatible thin films through a simple patterning method, we demonstrated that the platform had the potential to be utilized as a base material for DES with cell controllability. STATEMENT OF SIGNIFICANCE: The current first-generation drug-eluting stents (DES) would cause late and very late stent thrombosis due to the incomplete endothelialization of the metal stent material. In this work, we have developed a new DES platform composed of a 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer micropatterned by hydrogenated amorphous carbon (a-C:H). Two types of differently micropatterned a-C:H stent surface were made. Our studies revealed that the micropatterned a-C:H/MPC polymer substrates could effectively enhance the endothelial cell (EC) proliferation, simultaneously suppressing the platelet adhesion, becoming a highly biocompatible material especially for indwelling devices including a drug-release device. The new drug-release platform could be utilized as a base material for cell-controllable coating on DES.


Subject(s)
Carbon/chemistry , Human Umbilical Vein Endothelial Cells/metabolism , Membranes, Artificial , Methacrylates/chemistry , Neointima/metabolism , Phosphorylcholine/analogs & derivatives , Polymers/chemistry , Thrombosis/prevention & control , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacology , Human Umbilical Vein Endothelial Cells/pathology , Humans , Neointima/pathology , Phosphorylcholine/chemistry , Surface Properties , Thrombosis/metabolism , Thrombosis/pathology
9.
Rinsho Ketsueki ; 58(4): 323-325, 2017.
Article in Japanese | MEDLINE | ID: mdl-28484160

ABSTRACT

A 44-year-old woman had repeated bacterial infections because of hypoplastic myelodysplastic syndrome; therefore, she underwent allogeneic hematopoietic cell transplantation. Broad spectrum antibiotics were administered because she had bacterial infection and pneumonia 2 weeks before undergoing transplantation. On day19 after transplantation, she suddenly presented with hemoptysis. Stenotrophomonas maltophilia was considered to be the cause of hemorrhagic pneumonia, which required ventilation support, massive transfusion, and catecholamine administration. However, she died 8 h after the onset of hemoptysis. Severe S. maltophilia infections may occur in patients with immunocompromised conditions such as those after allogeneic hematopoietic cell transplantation.


Subject(s)
Bone Marrow Transplantation/adverse effects , Gram-Negative Bacterial Infections/microbiology , Myelodysplastic Syndromes/therapy , Pneumonia, Bacterial/microbiology , Stenotrophomonas maltophilia/isolation & purification , Adult , Fatal Outcome , Female , Gram-Negative Bacterial Infections/therapy , Humans , Pneumonia, Bacterial/therapy
10.
Rinsho Ketsueki ; 56(7): 889-94, 2015 Jul.
Article in Japanese | MEDLINE | ID: mdl-26251154

ABSTRACT

A 64-year-old woman underwent reduced-intensity conditioning cord blood transplantation (RIC-CBT) for refractory acute myeloid leukemia (AML). A 6/6 antigen-level HLA-identical cord blood from a male infant was transfused. After successful engraftment with complete donor chimerism, the patient developed mixed chimera (XX 8.8%) on day 82. Tapering of tacrolimus was started on day 96. Bone marrow chimerism analysis showed a decreasing recipient cell population (XX 2.2%) on day 117 and tacrolimus was discontinued with no clinical signs of GVHD on day 123. However, pancytopenia with agranulocytosis was detected on day 138. She was diagnosed as having secondary graft failure associated with Coombs-positive immune hemolytic anemia and immune thrombocytopenia (ITP). At the same time, the percentage of recipient T cell chimerism in peripheral blood was about 50% and the B cell population showed lambda light chain restriction. On day 180, she received a second RIC-CBT due to lack of improvement of agranulocytosis. A single dose of rituximab was administered on day - 11 before the second CBT to eliminate the activated B cells. Prompt neutrophil engraftment was achieved and both hemolytic anemia and ITP also showed resolution. She is currently well (30 months after the second CBT), showing normal blood cell counts and complete second donor chimerism of marrow cells.


Subject(s)
Anemia, Hemolytic/immunology , Arthritis, Rheumatoid/immunology , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/therapy , Thrombocytopenia/immunology , Anemia, Hemolytic/complications , Arthritis, Rheumatoid/complications , Cord Blood Stem Cell Transplantation , Female , Fetal Blood/transplantation , Humans , Leukemia, Myeloid, Acute/complications , Male , Middle Aged , Remission Induction , Thrombocytopenia/complications , Treatment Failure
11.
Ann Hematol ; 94(11): 1885-90, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26251157

ABSTRACT

Differential diagnosis between transthyretin (TTR) and immunoglobulin light-chain (AL) cardiac amyloidoses is essential due to significantly different prognoses and therapeutic options. Therefore, clinical characteristics of patients with biopsy-proven cardiac amyloidosis were investigated to differentiate TTR from AL amyloidosis. From September 2006 to May 2014, 46 patients were confirmed to have cardiac amyloidosis (TTR, n = 28; AL, n = 18) in our institute. The median age of patients with TTR amyloidosis was 78 years (range 61-90) with 27 (96 %) males, while that of patients with AL amyloidosis was 66 (range 52-76) with 12 (67 %) males. There were no statistically significant differences in echocardiographic findings regarding left ventricular (LV) systolic function or diastolic dysfunction between the two groups. Interestingly, serum brain natriuretic peptide (BNP) levels in patients with AL amyloidosis were significantly higher than those in TTR amyloidosis patients. In contrast, the LV wall was significantly thicker in patients with TTR amyloidosis than in those with AL amyloidosis. Therefore, the ratio of BNP to LV mass index (LVMI) at presentation in AL amyloidosis patients was significantly higher than that in TTR patients (6.7 vs 2.9, p = 0.0006). A BNP-LVMI ratio of less than 3.5 had a diagnostic sensitivity and specificity for TTR amyloidosis of 71 and 83 %, respectively. One-year overall survival was 88.7 % in the patients with TTR amyloidosis and 23.7 % in the patients with AL amyloidosis. Our analysis indicates that the BNP-LVMI ratio, as well as age and sex, may be useful parameters for distinguishing TTR from AL cardiac amyloidosis.


Subject(s)
Amyloid Neuropathies, Familial/diagnostic imaging , Amyloid Neuropathies, Familial/pathology , Amyloidosis/diagnostic imaging , Amyloidosis/pathology , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/pathology , Aged , Aged, 80 and over , Diagnosis, Differential , Echocardiography , Female , Humans , Immunoglobulin Light Chains/adverse effects , Immunoglobulin Light-chain Amyloidosis , Male , Middle Aged , Retrospective Studies
12.
Rinsho Ketsueki ; 56(12): 2452-5, 2015 Dec.
Article in Japanese | MEDLINE | ID: mdl-26725354

ABSTRACT

A 45-year-old man was diagnosed with t(8;21) positive acute myelogenous leukemia and failed to achieve complete remission (CR) after the first induction chemotherapy. He was then treated with high-dose cytarabine and achieved CR. Molecular relapse was detected during post-remission therapy and he underwent myeloablative bone marrow transplantation from his HLA-matched sibling donor. One year after transplantation, he developed an intractable anal fistula during treatment of chronic GVHD. Colonoscopy showed longitudinal ulcers and cobblestone appearance, and histopathological examination revealed non-caseating epithelioid granuloma. According to these findings, he was diagnosed with Crohn's-like chronic gastrointestinal inflammatory disease. He was treated with enteral nutrition, mesalazine and dose re-escalation of cyclosporine, but these therapies were not effective. Therefore, we decided to treat him with infliximab. After starting treatment with infliximab, his abdominal symptoms and the anal fistula showed prompt improvement. There are few reports regarding the efficacy of infliximab for gastrointestinal chronic GVHD. Our experience suggests that infliximab could be useful for the treatment of Crohn's-like gastrointestinal inflammatory disease.


Subject(s)
Bone Marrow Transplantation , Gastrointestinal Diseases/pathology , Gastrointestinal Diseases/therapy , Graft vs Host Disease/therapy , Infliximab/therapeutic use , Leukemia, Myeloid, Acute/therapy , Cytarabine/therapeutic use , Gastrointestinal Diseases/diagnosis , Graft vs Host Disease/diagnosis , Humans , Leukemia, Myeloid, Acute/diagnosis , Male , Middle Aged , Transplantation, Homologous
13.
Rinsho Ketsueki ; 56(12): 2472-6, 2015 Dec.
Article in Japanese | MEDLINE | ID: mdl-26725358

ABSTRACT

A 66-year-old man showed central nervous system (CNS) and epididymis involvement after concurrent chemoradiotherapy for extranodal natural killer/T-cell lymphoma, nasal type (ENKL). The patient experienced continuous nasal obstruction. CT revealed a mass in the nasal cavity and paranasal sinuses. Biopsy of the nasal cavity mass showed it to be ENKL. Based on bone marrow biopsy and 18F-FDG PET/CT findings, the clinical stage was suspected to be IIE. The sites involved were the nasal cavity, paranasal sinuses, and cervical lymph nodes. We performed concurrent chemoradiotherapy consisting of a 67% dose of DeVIC and involved field radiation therapy towards his head and neck. Head and neck CT confirmed a therapeutic response. After receiving concurrent chemoradiotherapy, the patient complained of perineal discomfort. Ultrasonography revealed swelling of the left epididymis. Left epididymis biopsy showed ENKL involvement and lumbar puncture revealed CNS involvement. The findings of this case suggest that evaluation of CNS involvement might be an essential part of the initial workup for some ENKL patients.


Subject(s)
Central Nervous System Neoplasms/pathology , Epididymis/pathology , Lymphoma, Extranodal NK-T-Cell/drug therapy , Nose Neoplasms/drug therapy , Aged , Central Nervous System Neoplasms/therapy , Chemoradiotherapy/methods , Epididymis/drug effects , Humans , Lymphoma, Extranodal NK-T-Cell/complications , Lymphoma, Extranodal NK-T-Cell/pathology , Male , Neoplasm Invasiveness , Nose Neoplasms/complications , Nose Neoplasms/diagnosis , Nose Neoplasms/pathology
14.
Rinsho Ketsueki ; 55(4): 450-5, 2014 04.
Article in Japanese | MEDLINE | ID: mdl-24850457

ABSTRACT

Cardiac involvement is by far the most relevant factor impacting poor outcomes of patients with systemic light-chain (AL) amyloidosis. Median survival of patients with symptomatic cardiac AL amyloidosis is less than 6 months. Approximately two-thirds of these patients die suddenly due to ventricular arrhythmias and electromechanical dissociation. We report a 56-year-old female with very severe cardiac AL amyloidosis (NT-proBNP 13,355 ng/l, troponin T 0.16 µg/l, and systolic blood pressure 100 mmHg), who was successfully treated with diuretics and an implantable cardioverter-defibrillator (ICD) and has survived for more than 4 years, to date. During the 4-year period after receiving the ICD, she experienced several episodes of sustained ventricular tachycardia and ventricular fibrillation, all successfully terminated by anti-tachycardia pacing or electrical shock. The benefit of ICD for cardiac AL amyloidosis is unclear since there have been only a few reports of successful use of this therapy for patients with cardiac AL amyloidosis. Recently, new treatment options for AL amyloidosis, such as bortezomib and lenalidomide, have shown high response rates and improved outcomes. It is important to identify those cardiac amyloidosis patients who might be more likely to benefit from ICD implantation.


Subject(s)
Amyloidosis/etiology , Amyloidosis/therapy , Cardiomyopathies/etiology , Cardiomyopathies/therapy , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Multiple Myeloma/complications , Tachycardia, Ventricular/etiology , Tachycardia, Ventricular/therapy , Female , Humans , Middle Aged , Severity of Illness Index , Time Factors , Treatment Outcome
15.
J Infect Chemother ; 20(4): 282-4, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24485325

ABSTRACT

The benefit of endotoxin absorption therapy (direct hemoperfusion with polymyxin B-immobilized fiber: PMX-DHP) for severe septic patients is still controversial. There are limited data on the clinical experience and efficacy of PMX-DHP for septic patients with hematological disorders. At our institution, 16 patients with hematological diseases underwent PMX-DHP therapy for gram-negative septic shock from February 2006 to March 2012. Most of the patients had severe neutropenia (median neutrophil counts: 7/µL) due to intensive chemotherapy for their hematological diseases. After the PMX-DHP therapy, six patients recovered from the shock status (favorable group) and ten died of the sepsis (unfavorable group). We analyzed the differences between the two groups based on clinical characteristics just before PMX-DHP therapy. Regarding sequential organ failure assessment (SOFA) score, which is a scoring system to determine the degree of organ dysfunction, all patients in the favorable group scored less than 11. The sensitivity and specificity of SOFA score less than 11 for the therapeutic efficacy were 100% and 80%, respectively. Our results suggest that septic patients with hematological diseases may not be a candidate for PMX-DHP therapy when they have already developed serious organ dysfunction.


Subject(s)
Hematologic Diseases/microbiology , Hemoperfusion/instrumentation , Polymyxin B , Sepsis/blood , Sepsis/therapy , Adult , Aged , Female , Hemoperfusion/methods , Humans , Male , Middle Aged , Polystyrenes
16.
Rinsho Ketsueki ; 54(2): 219-23, 2013 Feb.
Article in Japanese | MEDLINE | ID: mdl-23470831

ABSTRACT

A 46-year-old woman was urgently admitted to our hospital due to acute renal failure, liver dysfunction, disseminated intravascular coagulation, shock status, and impaired consciousness. About 1 day prior to admission, she developed a high-grade fever, bilateral lower leg pain, and multiple small papules. She was diagnosed with streptococcal toxic shock syndrome (STSS) caused by Streptococcus dysgalactiae subsp. equisimilis (SDSE) associated with acute myeloid leukemia. The emm gene type of the isolated SDSE was shown to be stG2078. Her invasive streptococcal infection resolved with immediate administration of meropenem and continuous hemodiafiltration. However, she died of septic shock caused by multidrug-resistant Pseudomonas aeruginosa one month after admission. Recently, epidemiological studies have shown increasing numbers of invasive SDSE infections, including STSS and necrotizing fasciitis, often among immunocompromised patients. This suggests that hematologists as well as primary care doctors need to be aware of the possibility of the invasive infections caused by SDSE. An influenza-like illness consisting of a fever, lower extremity pain, and diarrhea are common initial symptoms in STSS patients. Awareness of these prodromal symptoms could lead to the early diagnosis of the illness and prompt initiation of antibiotic treatment.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Shock, Septic/microbiology , Streptococcal Infections/drug therapy , Streptococcus/isolation & purification , Fatal Outcome , Female , Humans , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/diagnosis , Middle Aged , Shock, Septic/diagnosis , Streptococcal Infections/complications , Streptococcal Infections/diagnosis
18.
Kansenshogaku Zasshi ; 86(3): 300-5, 2012 May.
Article in Japanese | MEDLINE | ID: mdl-22746054

ABSTRACT

A 63-year-old man had been treated with intensive chemotherapy for acute myeloid leukemia. On the 49th hospital day, he had febrile neutropenia after the second course of induction chemotherapy. On the 53 rd hospital day, he presented with hemoptysis and developed acute respiratory failure requiring ventilator support within several hours. On the 54th hospital day, the patient died with hemorrhagic respiratory infection. Stenotrophomonas maltophilia was detected in bacterial cultures of his blood, bronchoalveolar lavage, and sputum. To our knowledge, nine cases of fatal hemorrhagic pneumonia caused by S. maltophilia have been reported in the literature. All the patients had hematological neoplasms and were severely neutropenic after one or two intensive chemotherapy regimens. They died shortly (within 3 days) after the onset of the hemorrhagic pneumonia. Management of the infection caused by S. maltophilia is hampered by high-level intrinsic resistance to multiple antibiotics and the increasing occurrence of acquired resistance to co-trimoxazole and fluoroquinolones. It would be important to keep in mind that hemorrhagic respiratory infection caused by S. maltophilia may lead to a fulminant and lethal course in severely neutropenic patients with hematological neoplasms and to recognize which antibiotic agents are more sensitive to S. maltophilia in each institution.


Subject(s)
Gram-Negative Bacterial Infections/complications , Hemorrhage/etiology , Leukemia, Myeloid, Acute/drug therapy , Lung Diseases/etiology , Pneumonia, Bacterial/complications , Stenotrophomonas maltophilia , Antibiotics, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Fatal Outcome , Humans , Leukemia, Myeloid, Acute/complications , Male , Middle Aged
19.
Plant Cell Physiol ; 46(1): 245-9, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15659439

ABSTRACT

We found novel vesicles derived from rough endoplasmic reticulum (ER) in rice endosperm. The novel vesicles had characteristic structures different from that of the ER-derived protein body type I and the Golgi-derived dense vesicles. Immunocytochemical analysis revealed that the novel vesicles are derived directly from the aggregates of vacuolar storage proteins in the rough ER. In addition, BiP, an ER-resident molecular chaperone, was localized in the novel vesicles, but also in protein storage vacuoles (PSVs). These results suggest that the novel vesicles mediate transport of vacuolar storage proteins directly from the ER to PSVs in rice endosperm.


Subject(s)
Endoplasmic Reticulum, Rough/metabolism , Endoplasmic Reticulum, Rough/ultrastructure , Oryza/metabolism , Oryza/ultrastructure , Plant Proteins/metabolism , Arabidopsis Proteins , Carrier Proteins/metabolism , Microscopy, Immunoelectron
20.
Biosci Biotechnol Biochem ; 68(8): 1728-36, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15322357

ABSTRACT

Tonoplast intrinsic proteins (TIPs) belong to an aquaporin family of proteins that function as water-transport channels. In this study, we isolated and characterized three novel rice cDNAs for OsTIP1, OsTIP2, and OsTIP3 that are homologous to rice gamma-TIP cDNA. Northern blot hybridization analyses revealed that rice gamma-TIP was expressed in all plant organs. OsTIP1 was expressed in mature seed embryos and during early seed germination. OsTIP2 was expressed exclusively in roots. OsTIP3 was specifically expressed in seeds. These results suggest that the OsTIP1, OsTIP2, and OsTIP3 genes encode discrete, functionally specialized TIPs. Immunocytochemical analysis in rice endosperm cells revealed that rice gamma-TIP was localized only on the protein body type II (PB-II) membranes, whereas OsTIP3 was localized on the PB-II and the aleurone grain membranes. Although both the PB-II and the aleurone grain are derived from vacuoles, these results suggest that they may be derived from different types of vacuoles.


Subject(s)
Gene Expression Regulation, Plant , Membrane Proteins/metabolism , Oryza/metabolism , Plant Proteins/metabolism , Plant Structures/metabolism , Seeds/metabolism , Cloning, Molecular , DNA, Complementary/genetics , Membrane Proteins/genetics , Membranes/metabolism , Microscopy, Electron, Transmission , Oryza/genetics , Plant Proteins/genetics , Seeds/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...